Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 18/20 | 0.53 |
| ▸ | CA2 | P00918 | 18/20 | 0.53 |
| ▸ | CA12 | O43570 | 17/20 | 0.53 |
| ▸ | CA9 | Q16790 | 17/20 | 0.53 |
| ▸ | CA4 | P22748 | 13/20 | 0.53 |
| ▸ | CA6 | P23280 | 13/20 | 0.53 |
| ▸ | CA5A | P35218 | 13/20 | 0.53 |
| ▸ | CA7 | P43166 | 13/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 13/20 | 0.53 |
| ▸ | CA5B | Q9Y2D0 | 13/20 | 0.53 |
| ▸ | CA3 | P07451 | 12/20 | 0.53 |
| ▸ | CA13 | Q8N1Q1 | 12/20 | 0.53 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL603778 | 0.84 | CA1 (0.39) | CA1CA2CA12CA9CA4 | |
| SCHEMBL6038485 | 0.77 | CA1 (0.64) | CA1CA2CA12CA9CA4 | |
| SCHEMBL10783974 | 0.76 | CA1 (0.49) | CA1CA2CA12CA9CA4 | |
| SCHEMBL5014186 | 0.76 | CA1 (0.70) | CA1CA2CA12CA9CA4 | |
| SCHEMBL11665653 | 0.75 | CA12 (0.65) | CA1CA2CA12CA9CA4 | |
| SCHEMBL603531 | 0.72 | CA2 (0.56) | CA1CA2CA12CA9CA4 | |
| SCHEMBL31451546 | 0.72 | CA2 (0.56) | CA1CA2CA12CA9CA4 | |
| SCHEMBL24051716 | 0.72 | CA1 (0.44) | CA1CA2CA12CA9CA4 | |
| SCHEMBL7194983 | 0.72 | CA1 (0.47) | CA1CA2CA12CA9CA4 | |
| SCHEMBL12173253 | 0.72 | CA1 (0.54) | CA1CA2CA12CA9CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268494-A1 | SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS | Merck Frosst Canada & Co. (CA) | 2003-01-02 | — | — | EP | disclosed |
| US-6498151-B2 | PROTEIN TYROSINE PHOSPHATASES INHIBITORS, ESPECIALLY AS ANTIDIABETIC AGENTS | MERCK FROSST CANADA & CO. (CA) | 2002-12-24 | — | — | US | disclosed |
| US-20020091104-A1 | Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors | MERCK FROSST CANADA LTD. (CA) | 2002-07-11 | — | — | US | disclosed |
| WO-2001070753-A1 | SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091104-A1 | Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors | PTPRF, PTPRS, PTPRO | CA1 4360/4885CA2 2577/4885CA12 4526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.